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Abstract
Background: This study was aimed to explore the role of long noncoding RNA C17orf91 and its potential
mechanisms in ovarian cancer development.
Results: To assess its role in ovarian cancer, microarray datasets (GSE14407, GSE30587, and GSE17260) in Gene
Expression Omnibus (GEO) were utilized to assess the expression and clinical significance of C17orf91 in ovarian
cancer. Next, loss-of-function studies were performed to establish the role of C17orf91 and the underlying
mechanisms in ovarian cancer development. It was found that elevated expression of C17orf91 was observed in
omental metastases when compared with matched primary ovarian tumors(GSE30587, P = 0.016). Moreover, Log
Rank analysis revealed that increased expression of C17orf91 was associated with shorter progression free
survival(PFS)(HR = 1.90(1.19-3.03), P = 0.008). Overall survival(OS) also showed a similar trend, but did not reach
statistical significance(HR = 1.75(0.97-3.13), P = 0.061). Loss-of-function studies further demonstrated that C17orf91
repression impaired migration, invasion and viability of ovarian cancer cells, and downregulated the pro-metastatic
gene, MYC, at both mRNA and protein level.
Conclusion: Collectively, our findings revealed that C17orf91 was a potential prognostic marker and functioned as
an oncogene in ovarian cancer. It remains to be seen whether modulation of C17orf91 expression will cause
phenotypic changes in vivo.
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Background
Ovarian cancer is the most lethal gynecological cancer
and the majority of the patients are not diagnosed until
advanced stages. Over the past decades, little improve-
ment in overall survival has been achieved despite
advances in chemotherapeutic agents [1]. Better under-
standing of the mechanisms involved in ovarian cancer
development is of great importance in overcoming this
malignancy.
Compelling evidence have indicated a large-scale
regulatory network generated by noncoding RNAs,
including microRNAs(miRNAs) and long noncoding
RNAs(lncRNAs). Integrated analyses of the cancer
genome and transcriptome have identified profound
alterations in noncoding genes [2, 3]. Although nu-
merous studies have helped unveiling the functions of
miRNAs in various cancers, only a small number of
functional lncRNAs have been thoroughly character-
ized to date. So far, lncRNAs have been involved in
the regulation of various cellular processes, including
but not limited to cell growth, cell cycle, apoptosis
and motility [4]. C17orf91, also known as MIR22HG
or MGC14376, is a long non-coding RNA(lncRNA)
located on chromosome 17p13 [5, 6]. It is the host
gene of miR-22 [5, 6]. Previous studies have linked
miR-22 to a great number of activities, such as
tumorigenesis, epigenetic modification, embryonic de-
velopment [7]. However, the function of its host gene
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C17orf91 has not yet been defined in any conditions,
including cancer [8, 9].
In this study, we tried to analyze C17orf91 expression
and its clinical significance in ovarian cancer and to
explore its role in ovarian cancer development.
Methods
GEO datasets
The publicly available microarray datasets used in our
study is described in GEO database(GSE14407, GSE30587
and GSE17260). GSE14407 dataset was used to explore the
differential expression of C17orf91 (probe ID: 214696_at)
between normal ovarian surface epithelium(n = 12) and
primary ovarian cancers(n = 12). GSE30587 dataset was
used to determine the differential expression of C17orf91
(probe ID: 8011193) between paired primary ovarian can-
cer tissues(n = 9) and their corresponding omental metas-
tases(n = 9). Relationship between C17orf91 expression
(probe ID: A_23_P49610) and ovarian cancer outcome was
determined using the gene expression data in 110 ovarian
cancer patients(GSE17260).
Cell lines
Human serous ovarian cancer cell Hey was originally ob-
tained from M.D. Anderson Cancer Center (Houston,
TX) and cultured in RPMI medium 1640 plus 10 % fetal
bovine serum with penicillin/streptomycin. 293 T cell
line was originally obtained from the cell bank of
Chinese Academy of Science (Shanghai) and cultured in
DMEM plus 10 % fetal bovine serum with penicillin/
streptomycin.
Constructs
PLKO-Scramble-shRNA was purchased from Addge-
ne(Addgene #1864). PLKO-C17orf91-shRNA plasmids
were constructed according to PLKO.1 protocol. The
sequences of C17orf91 shRNA were obtained from The
RNAi Consortium (TRC, MISSION® TRC shRNA li-
brary, Sigma) and shown in Additional file 1: Table S1.
Lentiviral infection
For producing lentiviral particles, 293 T cells were
seeded in 3.5-cm dishes at a density of 4 × 105 per dish
and transfected with PLKO-Scramble-shRNA/PLKO-
C17orf91-shRNA, as well as packing plasmids psPAX2
(0.75 μg) (Addgene#12260) and pMD2.G (0.25 μg)
(Addgene #12259) using Attractene Transfection Re-
agent (QIAGEN). Forty-eight hours post transfection,
virus-containing medium (2 ml) was harvested, filtered,
mixed with 2 ml of freshsly prepared medium, supple-
mented with 8 μg/ml polybrene (Sigma) and added to
3 × 105 Hey cells seeded in a 3.5-cm dish the day before.
Puromycin (2 μg/ml) was supplemented 48 h after
infection. The cells were selected for 2 days and then
used for various assays.
QPCR
Briefly, reverse transcription reactions were carried out
using RevertAidTM First Strand cDNA Synthesis Kit
(Fermentas). QPCR was performed using SYBR® Premix
Ex Taq™ II (Perfect Real Time) Kit (TaKaRa, Dalian,
China) in ABI PRISM 7500 Sequence Detection System
(Applied Biosystems). Quantitative analysis was per-
formed using Comparative CT method. The relative
expression of each gene was normalized to the expres-
sion of GAPDH. Primers used in present study were
shown in Additional file 1: Table S1.
Western blot assay
Whole cell extracts were prepared in chilled RIPA lysis
buffer(Beyotime, China). 30 μg of lysates protein were
separated by SDS-PAGE using a 10 % polyacrylamide gel
and transferred to 0.45 μm PVDF membrane(Millipore).
Membranes were blocked with 5 % non-fat milk in PBS
containing 0.05 % Tween-20, blotted with MYC anti-
body(1:1000, CST) or GAPDH antibody(1:3000, beyo-
time) overnight, followed by goat anti-mouse antibody.
The images were scanned by LAS4000 device.
Measurement of cell migration and invasion
RTCA CIM-Plate was used to explore the effect of
C17orf91 on migration and invasion of ovarian cancer
cells. Migration and invasion assays were performed
according to protocols supplied by the manufacturers.
For invasion assay, the inserts were coated with BD
Matrigel (B.D. Biosciences). Briefly, 4 × 104 Scramble-
shRNA- and C17orf91-shRNA-transfected Hey cells
were added into the RTCA CIM-Plate and monitored by
xCELLigence (Roche) for 36 h.
Measurement of cell viability
RTCA E-plate was used to explore the effect of
C17orf91 on cell viability. Briefly, 2 × 103 Scramble-
shRNA- and C17orf91-shRNA-transfected Hey cells
were added into the RTCA E-Plate and monitored by
xCELLigence (Roche) for 96 h.
Statistical analysis
All data were analyzed with SPSS statistic software (SPSS
16.0). Student’s t test (two-tailed) was used to compare
two groups. The Log-rank test was used to determine
the relationship between C17orf91 expression and clin-
ical outcomes(progression free survival and overall sur-
vival). The Kaplan-Meier method was used to generate
survival curves. P-value <0.05 was considered statistically
significant.
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Results
Differential expression of C17orf91 between OSE, primary
tumors and omental metastases
To explore the clinical significance of C17orf91 in ovarian
cancer development, we first determined the differential
C17orf91 expression between serous ovarian cancer tis-
sues and normal ovarian surface epithelium(OSE) with re-
sort to the GEO datasets. It was found that C17orf91
expression appeared to be downrelulated in ovarian can-
cer tissues compared with OSE, though without statistical
significance(GSE14407, Fig. 1a, P = 0.078). However, ele-
vated expression of C17orf91 was observed in omental
metastases when compared with matched primary ovarian
tumors(GSE30587, Fig. 1b, P = 0.016).
The prognostic value of C17orf91 expression in ovarian
cancer
Next, we assessed the prognostic value of C17orf91
expression by taking advantage of the microarray dataset
(GSE17260) in Gene Expression Omnibus. Interestingly,
Log Rank (Mantel-Cox) analysis revealed that increased
expression of C17orf91 was associated with shorter pro-
gression free survival(PFS) (Fig. 2a, HR = 1.90(1.19-3.03),
P = 0.008). Overall survival(OS) also showed a similar
trend, but did not reach statistical significance(Fig. 2b,
HR = 1.75(0.97-3.13), P = 0.061).
Oncogenic role of C17orf91 in ovarian cancer
To explore the potential role of C17orf91 in ovarian can-
cer, we performed loss-of-function studies in Hey cells.
Stable C17orf91-shRNA clones as well as their respective
control clones were generated and examined for
C17orf91 mRNA by Real-time RT-PCR (Fig. 3a). Inter-
estingly, C17orf91 inhibition significantly decreased mi-
gration, invasion and viability of Hey cells (Fig. 3b–3d).
C17orf91 reglulated MYC expression in ovarian cancer
To further investigate the mechanism by which C17orf91
elicited its oncogenic role, we explored whether C17orf91
could regulate key pro-metastatic genes, such as KLF8
[10], MYC [11], SNAI2 [12], TWIST1 [13], ZEB1 [14] and
ZEB2 [15] in ovarian cancer. It was found that C17orf91
repression could reduce the expression of KLF8, MYC
and SNAI2 at mRNA level (Fig. 4a). Subsequent western
blot assay was focused on MYC partly because it was the
most obviously altered gene. It was found that C17orf91
downregulation also decreased the protein level of MYC
(Fig. 4b).
Discussion
C17orf91, also known as MIR22HG, was a stress re-
sponsive lncNRA [16]. Previous studies showed that
stress responsive lncRNAs might be linked to cancer
progression [17–19]. Knockdown of LSINCT5 signifi-
cantly impaired the proliferation of both breast and
ovarian cancer cells [17]. Another stress responsive
lncRNA which might also be involved in cancer pro-
gression is PRINS(psoriasis susceptibility-related RNA
gene induced by stress). It was found that PRINS
played a protective role in cells exposed to stress, and
moreover, elevated PRINS expression in the epidermis
might contribute to psoriasis susceptibility [18]. Fur-
ther studies revealed that PRINS could regulate the
expression of G1P3, an inferno-inducible gene with
anti-apoptotic effects in cancer cells [19]. In this
study, we also demonstrated that the stress responsive
lncRNA C17orf91 could regulate the migration, inva-
sion and viability of ovarian cancer cells.
Additionally, we characterized the clinical signifi-
cances of C17orf91 in ovarian cancer tissues by taking
advantages of publicly available microarray datasets in
GEO database. It was noticeable that C17orf91 ex-
pression appeared to be downregulated in ovarian
cancer tissues compared with OSE though without
statistical significance. Indeed, such findings were not
only limited in our study. For example, the well-
known pro-metastatic gene miR-10b was found to be
downregulated in primary breast tumors compared
Fig. 1 Differential expression of C17orf91 between OSE, primary tumors and omental metastases. a C17orf91 expression appeared to be
decreased in primary tumors compared with OSE, but do not reach statistical significance(GSE14407). b Paired t-test shows that C17orf91
expression was significantly elevated in omental metastases relative to corresponding primary tumors(GSE30587)
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with normal breast tissues [20, 21]. Our findings, to-
gether with findings from other laboratories, have in-
dicated that oncogenes are not always upregulated in
cancer tissues when compared with corresponding
normal tissues. This may also be applicable for tumor
suppressors which are commonly downregulated in
cancer tissues relative to normal controls.
Previous studies indicated that decreased C17orf91 ex-
pression was associated with a worse prognosis in breast
and lung cancer patients [8, 9, 22]. However, our data re-
vealed that increased C17orf91 expression correlated with
shorter PFS and OS. These discrepant findings might be
related to the fact that the prognostic value of C17orf91
was cancer specific. Mechanismly, we demonstrated that
C17orf91 repression could downregulate the MYC expres-
sion at both mRNA and protein level, indicating that the
oncogenic role elicited by C17orf91 might be partly medi-
ated by the induction of MYC expression.
Fig. 2 The prognostic value of C17orf91 expression in ovarian cancer(GSE17260). a Log Rank (Mantel-Cox) analysis revealed that increased
expression of C17orf91 was associated with shorter progression free survival(PFS). b Overall survival(OS) also showed a similar trend, but did not
reach statistical significance. “Low” and “High” were classified according to the C17orf91 expression level. The median expression value for
C17orf91 was used as the cutoff point
Fig. 3 The oncogenic role of C17orf91 in ovarian cancer monitored by xCELLigence. a Construction of Hey cells that stably inhibited C17orf91
expression. b, c, d Inhibition of C17orf91 repressed migration (b), invasion (c), and viability (d) of ovarian cancer cells
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Conclusion
In conclusion, our findings revealed that C17orf91 was a
potential prognostic marker and functioned as an onco-
gene in ovarian cancer. It remains to be seen whether
modulation of C17orf91 expression will cause pheno-
typic changes in vivo.
Additional file
Additional file 1: Primers used in present study. (XLS 17 kb)
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